- $6.85m
- $2.30m
- $81.00m
- 62
- 77
- 54
- 71
Annual balance sheet for Aytu Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
R2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 48.1 | 49.6 | 19.4 | 23 | 20 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.63 | 28.2 | 21.7 | 28.9 | 23.6 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 75.4 | 105 | 59.9 | 72.8 | 61.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.893 | 8.7 | 6.3 | 3.87 | 1.52 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 153 | 266 | 138 | 136 | 118 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 28.8 | 109 | 64.4 | 69 | 62.2 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 58.3 | 128 | 91.5 | 97.1 | 90.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 95 | 138 | 46.1 | 39.4 | 27.7 |
Total Liabilities & Shareholders' Equity | 153 | 266 | 138 | 136 | 118 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |